株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

臨床試験用品の世界市場 - 2025年までの予測:製造、パッケージング、ロジスティクス、流通、保管

Clinical Trial Supplies Market by Products & Services (Manufacturing, Packaging, Logistics, Distribution, Storage), Phases ( l, ll, lll, lV), Drug Type (Small Molecule, Biologics),Therapeutic Areas (Oncology, Blood Disorders) - Global Forecast to 2025

発行 MarketsandMarkets 商品コード 926572
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.69円で換算しております。
臨床試験用品の世界市場 - 2025年までの予測:製造、パッケージング、ロジスティクス、流通、保管 Clinical Trial Supplies Market by Products & Services (Manufacturing, Packaging, Logistics, Distribution, Storage), Phases ( l, ll, lll, lV), Drug Type (Small Molecule, Biologics),Therapeutic Areas (Oncology, Blood Disorders) - Global Forecast to 2025
出版日: 2020年02月20日 ページ情報: 英文 159 Pages
概要

世界の臨床試験用品市場は、2020年の17億米ドルから、2025年までに25億米ドルに達し、CAGRで7.8%の成長が予測されています。この市場の成長は主に、製薬会社やバイオ製薬会社における研究開発費の増加と、臨床試験のグローバル化、規制の調和によって牽引されています。ただし、創薬・臨床試験のコスト増加は、予測期間中にこの市場の成長を抑制すると予想されています。

当レポートでは、世界の臨床試験用品市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

926572_4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW_FIGURE 11

目次

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 臨床試験用品市場の概要
  • 北米の臨床試験用品市場:薬剤タイプ別、国別
  • 臨床試験用品市場の地域別スナップショット

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第6章 臨床試験用品市場:サービス別

  • イントロダクション
  • 製造
  • パッケージング、ラベリング、ブラインド
  • コンパレータソーシング
  • ロジスティクス
  • 流通、保管、保持
  • ソリューション

第7章 臨床試験用品市場:フェーズ別

  • イントロダクション
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV
  • BA/BE研究

第8章 臨床試験用品市場:薬剤タイプ別

  • イントロダクション
  • 低分子薬
  • 生物学的製剤

第9章 臨床試験用品市場:治療分野別

  • イントロダクション
  • 腫瘍
  • 神経障害・精神障害
  • 消化器系疾患
  • 感染症・免疫系疾患
  • 血液疾患
  • その他

第10章 臨床試験用品市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第11章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合シナリオ

第12章 企業プロファイル

  • CATALENT, INC.
  • ALMAC GROUP
  • PAREXEL INTERNATIONAL CORPORATION
  • THERMO FISHER SCIENTIFIC, INC.
  • PCI SERVICES
  • UDG HEALTHCARE PLC.
  • BIOCAIR
  • BILCARE LIMITED
  • O&M MOVIANTO (OWENS & MINORの一部)
  • KLIFO A/S
  • CAPSUGEL (LONZA GROUPの一部)
  • INFOSYS LIMITED
  • PRA HEALTH SCIENCES, INC.
  • EUROFINS SCIENTIFIC
  • MARKEN (UPSの子会社)
  • SEVEILLAR CLINICAL TRIAL SUPPLIES PVT. LTD.
  • N-SIDE

第13章 付録

図表

LIST OF TABLES

  • TABLE 1: PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2018
  • TABLE 2: GLOBAL CANCER INCIDENCE, 2018 VS. 2025
  • TABLE 3: GLOBAL INCIDENCE OF THE TOP 10 FATAL DISEASES, 2015-2017 (MILLION)
  • TABLE 4: AVERAGE COST OF DRUGS APPROVED PER YEAR, 2004-2013
  • TABLE 5: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 6: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 7: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 8: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 9: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS SERVICES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 10: CLINICAL TRIAL SUPPLIES MARKET FOR DISTRIBUTION, STORAGE, AND RETENTION SERVICES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 11: CLINICAL TRIAL SUPPLIES MARKET FOR SOLUTIONS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 12: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 13: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 14: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 15: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 16: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 17: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 18: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 19: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 20: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 21: GLOBAL NUMBER OF CLINICAL TRIALS, BY THERAPEUTIC AREA (AS OF OCTOBER 2019)
  • TABLE 22: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 23: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 24: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGICAL AND MENTAL DISORDERS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 25: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 26: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 27: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 28: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 29: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 30: NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 31: NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 32: NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 33: NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 34: NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 35: NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017
  • TABLE 36: US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 37: US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 38: US: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 39: US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 40: NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2019)
  • TABLE 41: NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY COMPANY, 2017
  • TABLE 42: CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 43: CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 44: CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 45: CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 46: EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 47: EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 48: EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 49: EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 50: EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 51: GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 52: GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 53: GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 54: GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 55: UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 56: UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 57: UK: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 58: UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 59: NUMBER OF CLINICAL TRIALS STARTED IN FRANCE, BY COMPANY, 2017
  • TABLE 60: FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 61: FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 62: FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 63: FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 64: NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017
  • TABLE 65: ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 66: ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 67: ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 68: ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 69: SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 70: SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 71: SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 72: SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 73: ROE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 74: ROE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 75: ROE: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 76: ROE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 77: TOTAL NUMBER OF CLINICAL TRIALS IN APAC, BY THERAPEUTIC AREA, 2017
  • TABLE 78: APAC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 79: APAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 80: APAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 81: APAC: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 82: APAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 83: CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 84: CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 85: CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 86: CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 87: INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 88: INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 89: INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 90: INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 91: JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 92: JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 93: JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 94: JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 95: AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 96: AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 97: AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 98: AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 99: SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 100: SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 101: SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 102: SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 103: SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 104: SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 105: SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 106: SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 107: ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 108: ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 109: ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 110: ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 111: ROW: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 112: ROW: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 113: ROW: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 114: ROW: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 115: ROW: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 116: BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 117: BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 118: BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 119: BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 120: MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 121: MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 122: MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 123: MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 124: OTHER ROW COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • TABLE 125: OTHER ROW COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 126: OTHER ROW COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2018-2025 (USD MILLION)
  • TABLE 127: OTHER ROW COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 128: SERVICE LAUNCHES, 2017-2019
  • TABLE 129: AGREEMENTS & COLLABORATIONS, 2017-2019
  • TABLE 130: ACQUISITIONS, 2017-2019
  • TABLE 131: EXPANSIONS, 2017-2019
  • TABLE 132: OTHER DEVELOPMENTS, 2017-2019

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020 VS. 2025 (USD MILLION)
  • FIGURE 7: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020 VS. 2025 (USD MILLION)
  • FIGURE 8: CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE, 2020 VS. 2025 (USD MILLION)
  • FIGURE 9: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020 VS. 2025 (USD MILLION)
  • FIGURE 10: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
  • FIGURE 11: INCREASING R&D EXPENDITURE IN PHARMA AND BIOTECH INDUSTRIES TO DRIVE MARKET GROWTH
  • FIGURE 12: SMALL-MOLECULE DRUGS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2020
  • FIGURE 13: CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 14: CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 15: R&D SPENDING BY PHRMA MEMBER-COMPANIES, 2001-2017 (USD BILLION)
  • FIGURE 16: NUMBER OF REGISTERED CLINICAL TRIAL STUDIES (GLOBAL), 2011-2018
  • FIGURE 17: AVERAGE COST OF DEVELOPING ONE NEW APPROVED DRUG-INCLUDING THE COST OF FAILURES
  • FIGURE 18: R&D PIPELINE, BY THERAPY GROUP, 2018 & 2019
  • FIGURE 19: TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY, BY REGION (AS OF DECEMBER 2019)
  • FIGURE 20: TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA
  • FIGURE 21: NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT
  • FIGURE 22: US: PIPELINE SPLIT OF PHARMA/BIOTECH COMPANIES, BY PHASE (JANUARY 2019)
  • FIGURE 23: NUMBER OF CLINICAL TRIALS CONDUCTED IN EUROPE, BY COUNTRY, 2018
  • FIGURE 24: SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2011-2017
  • FIGURE 25: APAC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT
  • FIGURE 26: KEY DEVELOPMENTS IN THE CLINICAL TRIAL SUPPLIES MARKET, 2017-2019
  • FIGURE 27: GLOBAL CLINICAL TRIAL SUPPLIES MARKET SHARE ANALYSIS, 2018
  • FIGURE 28: CATALENT, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 29: THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 30: UDG HEALTHCARE: COMPANY SNAPSHOT (2018)
  • FIGURE 31: BILCARE LIMITED: COMPANY SNAPSHOT (2018)
  • FIGURE 32: OWENS & MINOR: COMPANY SNAPSHOT (2018)
  • FIGURE 33: LONZA GROUP: COMPANY SNAPSHOT (2018)
  • FIGURE 34: INFOSYS LIMITED: COMPANY SNAPSHOT (2018)
  • FIGURE 35: PRA HEALTH SCIENCES, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 36: EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2018)
  • FIGURE 37: UPS, INC.: COMPANY SNAPSHOT (2018)
目次
Product Code: PH 3772

"Increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the globalization of clinical trials & harmonization of regulations are driving the overall growth of the clinical trial supplies market"

The clinical trial supplies market is projected to reach USD 2.5 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 7.8%. The growth of this market is majorly driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the globalization of clinical trials & harmonization of regulations. However, the increasing cost of drug development and clinical trials is expected to restrain the growth of this market during the forecast period.

"Logistics services segment to account for the largest share of the clinical trial supplies market in 2020"

Based on service, the clinical trial supplies market is segmented into logistics; distribution, storage, and retention; packaging, labeling, and blinding; manufacturing; comparator sourcing; and solutions. The logistics services segment is expected to account for the largest share of the clinical trial supplies market during the forecast period. This can primarily be attributed to the globalization of clinical trials and the increasing number of trials involving temperature-sensitive products.

"Oncology segment to account for the largest share of the clinical trial supplies market, by therapeutic area, in 2020"

Based on the therapeutic area, the clinical trial supplies market is segmented into oncology, neurological and mental disorders, infectious and immune system diseases, digestive system diseases, blood disorders, and other therapeutic areas. The oncology segment is expected to account for the largest share of the market in 2020 and is estimated to register the highest growth during the forecast period majorly due to the high and growing number of research studies on cancer therapeutics and a large number of companies focusing on bringing innovative cancer drugs to the market.

"North America will continue to dominate the clinical trial supplies market during the forecast period"

In 2020, North America is estimated to be the largest regional market for clinical trial supplies, followed by Europe. The presence of well-established CROs and the high and growing investments in drug discovery and development by pharmaceutical and biopharmaceutical companies in North America are the major factors responsible for the large share of this region in the global market. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period majorly due to the growing number of CROs in the region and the presence of less-stringent regulations for clinical trials and patient recruitment in emerging Asia Pacific countries.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 36%, Tier 2 - 45%, and Tier 3 - 19%
  • By Designation: C-level - 33%, D-level - 40%, and Others - 27%
  • By Region: North America - 39%, Europe - 30%, Asia Pacific - 22%, and RoW - 9%

List of Companies Profiled in the Report:

  • Catalent, Inc. (US)
  • Almac Group (UK)
  • Parexel International Corporation (US)
  • Thermo Fisher Scientific, Inc. (US)
  • PCI Services (US)
  • UDG Healthcare Plc. (Ireland)
  • Biocair (UK)
  • Bilcare Limited (India)
  • O&M Movianto (US)
  • KLIFO A/S (Denmark)
  • Capsugel (Switzerland)
  • Infosys Limited (India)
  • PRA Health Sciences, Inc. (US)
  • Eurofins Scientific (Luxembourg)
  • Marken (US)
  • Seveillar Clinical Trial Supplies Pvt. Ltd. (India)
  • N-SIDE (Belgium)

Research Coverage:

This report provides a detailed picture of the global clinical trial supplies market. It aims at estimating the size and future growth potential of the market across different segments, such as service, phase, drug type, therapeutic area, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCES
  • 2.3 PRIMARY DATA
  • 2.4 MARKET SIZE ESTIMATION
    • 2.4.1 BOTTOM-UP APPROACH
    • 2.4.2 TOP-DOWN APPROACH
    • 2.4.3 GROWTH FORECAST
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
  • 4.2 NORTH AMERICAN CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE & COUNTRY, 2020
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE CLINICAL TRIAL SUPPLIES MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing R&D expenditure in the pharmaceutical & biopharmaceutical industry
      • 5.2.1.2 Globalization of clinical trials and harmonization of regulations resulting in the outsourcing of clinical trial activities
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Increasing cost of drug development and clinical trials
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Patent expirations
      • 5.2.3.2 Emerging markets
      • 5.2.3.3 Growth in the biologics market

6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE

  • 6.1 INTRODUCTION
  • 6.2 MANUFACTURING
    • 6.2.1 MANUFACTURING SERVICES INCLUDE FULL IN-HOUSE CGMP ANALYTICAL SERVICES, BIOANALYTICAL SERVICES, AND PARTICLE CHARACTERIZATION
  • 6.3 PACKAGING, LABELING, AND BLINDING
    • 6.3.1 INCREASING DEMAND FOR ADVANCED PACKAGING TO SUPPORT THE GROWTH OF THIS MARKET
  • 6.4 COMPARATOR SOURCING
    • 6.4.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
  • 6.5 LOGISTICS
    • 6.5.1 GLOBALIZATION OF CLINICAL TRIALS HAS DRIVEN THE DEMAND FOR LOGISTICS SERVICES
  • 6.6 DISTRIBUTION, STORAGE, AND RETENTION
    • 6.6.1 END-TO-END TRACKING OF DRUGS IS AN IMPORTANT FACTOR IN CLINICAL TRIALS
  • 6.7 SOLUTIONS
    • 6.7.1 AUTOMATION IN DRUG DISCOVERY AND CLINICAL TRIALS TO DRIVE MARKET GROWTH

7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE

  • 7.1 INTRODUCTION
  • 7.2 PHASE I
    • 7.2.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND PROPER SUPPLY AND DISTRIBUTION PLAY AN IMPORTANT ROLE IN THE SUCCESS OF A DRUG IN PHASE I TRIALS
  • 7.3 PHASE II
    • 7.3.1 PHASE II TRIALS ARE DESIGNED TO ASSESS THE EFFICACY OF DRUGS
  • 7.4 PHASE III
    • 7.4.1 INVOLVEMENT OF A LARGE NUMBER OF PATIENTS IN PHASE III TRIALS-A MAJOR FACTOR DRIVING MARKET GROWTH
  • 7.5 PHASE IV
    • 7.5.1 PHASE IV STUDIES ALLOW RESEARCHERS TO OBSERVE THE LONG-TERM EFFECTS OF A PARTICULAR DRUG IN A CONSIDERABLY LARGER POOL OF PATIENTS
  • 7.6 BA/BE STUDIES
    • 7.6.1 INCREASING PATENT EXPIRATION TO INCREASE THE DEMAND FOR BA/BE STUDIES

8 CLINICAL TRIAL SUPPLIES MARKET, BY DRUG TYPE

  • 8.1 INTRODUCTION
  • 8.2 SMALL-MOLECULE DRUGS
    • 8.2.1 EASE OF DEVELOPMENT OF SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH
  • 8.3 BIOLOGIC DRUGS
    • 8.3.1 INCREASING ADOPTION AND AFFORDABILITY OF BIOLOGIC DRUGS TO DRIVE MARKET GROWTH

9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
  • 9.2 ONCOLOGY
    • 9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
  • 9.3 NEUROLOGICAL AND MENTAL DISORDERS
    • 9.3.1 INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
  • 9.4 DIGESTIVE SYSTEM DISEASES
    • 9.4.1 PHARMACEUTICAL COMPANIES ARE INVESTING SIGNIFICANTLY IN R&D FOR THE DEVELOPMENT OF INNOVATIVE DRUGS FOR DIGESTIVE SYSTEM DISEASES
  • 9.5 INFECTIOUS AND IMMUNE SYSTEM DISEASES
    • 9.5.1 EMERGENCE OF NEW INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
  • 9.6 BLOOD DISORDERS
    • 9.6.1 HIGH GLOBAL BURDEN OF BLOOD DISORDERS HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
  • 9.7 OTHER THERAPEUTIC AREAS

10 CLINICAL TRIAL SUPPLIES MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
      • 10.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market
    • 10.2.2 CANADA
      • 10.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
  • 10.3 EUROPE
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany accounted for the largest share of the European market
    • 10.3.2 UK
      • 10.3.2.1 Favorable government initiatives in the UK to support market growth
    • 10.3.3 FRANCE
      • 10.3.3.1 High number of oncology clinical trials in France to drive market growth
    • 10.3.4 ITALY
      • 10.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth
    • 10.3.5 SPAIN
      • 10.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
    • 10.3.6 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 CHINA
      • 10.4.1.1 Low cost of clinical trials and large pharmaceutical R&D footprint in China to drive market growth
    • 10.4.2 INDIA
      • 10.4.2.1 Low-cost services and availability of skilled workforce to support market growth in India
    • 10.4.3 JAPAN
      • 10.4.3.1 Government initiatives for drug innovation to support market growth in Japan
    • 10.4.4 AUSTRALIA
      • 10.4.4.1 Low cost of conducting clinical trials to support market growth in Australia
    • 10.4.5 SINGAPORE
      • 10.4.5.1 Increasing focus of various companies on Singapore to support market growth
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Government support for drug innovation to support market growth in South Korea
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 REST OF THE WORLD
    • 10.5.1 BRAZIL
    • 10.5.2 MEXICO
    • 10.5.3 OTHER ROW COUNTRIES

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET SHARE ANALYSIS, 2018
  • 11.3 COMPETITIVE SCENARIO
    • 11.3.1 SERVICE LAUNCHES
    • 11.3.2 AGREEMENTS AND COLLABORATIONS
    • 11.3.3 ACQUISITIONS
    • 11.3.4 EXPANSIONS
    • 11.3.5 OTHER DEVELOPMENTS

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 12.1 CATALENT, INC.
  • 12.2 ALMAC GROUP
  • 12.3 PAREXEL INTERNATIONAL CORPORATION
  • 12.4 THERMO FISHER SCIENTIFIC, INC.
  • 12.5 PCI SERVICES
  • 12.6 UDG HEALTHCARE PLC.
  • 12.7 BIOCAIR
  • 12.8 BILCARE LIMITED
  • 12.9 O&M MOVIANTO (PART OF OWENS & MINOR)
  • 12.10 KLIFO A/S
  • 12.11 CAPSUGEL (PART OF LONZA GROUP)
  • 12.12 INFOSYS LIMITED
  • 12.13 PRA HEALTH SCIENCES, INC.
  • 12.14 EUROFINS SCIENTIFIC
  • 12.15 MARKEN (A SUBSIDIARY OF UPS)
  • 12.16 SEVEILLAR CLINICAL TRIAL SUPPLIES PVT. LTD.
  • 12.17 N-SIDE

Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS